Sally is focused on developing preclinical studies for therapeutic programs at Life Edit Therapeutics.
She has six years of experience in developing AAV-based gene therapy approaches for neurodevelopmental disorder.
Sally received PhD in Neuroscience from University of North Carolina at Chapel Hill.